



skinuvita



The future of phototherapy for skin diseases

A chronic skin disease can be a high burden...

Access to effective treatments is essential to control flare-ups



PSORIASIS

125 mio Patients

Dry plaques & irritated skin

Intense itching

Social stigma

High emotional burden

20 % patients with severe symptoms



ATOPIC DERMATITIS

204 mio Patients

Phototherapy is a well-proven therapy

First-line treatment for moderate to severe cases - with 311nm narrowband UVB light




Effective



75 % clearance rate for Psoriasis

Targeted & Tolerable



Targeted treatment possible, can be applied without injections & systemic immune suppression

Good cost-benefit ratio



Significantly lower treatment costs compared to biologics

Problem: Phototherapy is often not accessible

Patients who can't commute frequently to therapy centers need to switch to system therapy



**25 sessions
on site required**

- ⚡ *3-6 sessions per week*
- ⚡ *during office hours*
- ⚡ *Limited availabilites*

Problem:

53 %

of Patients

**can't adhere to
therapy frequency**

- ⚡ *Rural areas lack therapy sites*
- ⚡ *Working hours clash*
- ⚡ *Hard to align with childcare*


Solution: Home therapy with Skinuvita

Skinuvita enables a safe phototherapy from home – medically supervised via tele-medicine



THERAPY MANAGER

Tele-monitoring interface for dermatologists



THERAPY APP

Digital guidance for patients and reporting of skin reaction



CONNECTED HARDWARE

Direct dosage transmission to smart therapy devices – provided by Skinuvita

Clinical data shows strong benefits

Multicentric clinical trial in Germany evaluating Skinuvita, n= 759 therapy sessions; 29 patients



EXCELLENT SAFETY

Full medical & regulatory compliance for home-use



82 % THERAPY RESPONDERS

= Improved Dermatology Life Quality Index (DLQI)



87 % ADHERENCE

Prescribed sessions done by patients within 48h hours



BEFORE



AFTER

Dynamic market adoption in public healthcare system

Long-term contracts with public insurances and strong interest from dermatologists to prescribe Skinuvita



Jan '25

EU certification as medical device (MDR IIa)



April '25

7 public insurances close contracts with Skinuvita



Oct '25

181 dermatologists sign letter of Intent



Ready to scale across Europe!

Looking forward to meet you!

Let's have skin in the game



Bojana Petkovic
Art Director

bojana@skinvita.de



Maria Araujo, M.A.
Product Owner

maria@skinvita.de



Jan B. Elsner, M.Sc.
CEO

jan@skinvita.de